Clinical trials: Interstitial Cystitis/Painful Bladder Syndrome
- Condition Interstitial Cystitis/Painful Bladder Syndrome
- Funder type Industry (pharma, biotech, devices)
Hunner Type Interstitial Cystitis
A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Hunner Type Interstitial Cystitis
- Trial name
- NCT06752603
- Testing
- ONO-1110
- Where
- 20 sites in Japan
- Volunteers
- 57 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Interstitial Cystitis
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms following LiRIS…
- Trial name
- NCT01824303
- Testing
- LiRIS 400 mg
- Where
- 17 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Allergan
Interstitial Cystitis, Bladder Pain Syndrome
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and…
- Trial name
- NCT05737121
- Testing
- VNX001, Lidocaine, Heparin
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vaneltix Pharma, Inc.
Cystitis, Interstitial
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
The purpose of this study is to determine whether PF-04383119 is effective in the treatment of pain associated with interstitial cystitis.
- Trial name
- NCT00601484
- Testing
- PF-04383119
- Where
- 34 sites in United States
- Volunteers
- 65 people
- Sponsor
- Pfizer
Interstitial Cystitis
Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to determine the safety and pharmacokinetics of TTI-1612 in women with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT01559961
- Testing
- TTI-1612
- Where
- 4 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Trillium Therapeutics Inc.
Interstitial Cystitis
Safety Study of LiRIS in Interstitial Cystitis (IC) Patients
The purpose of this study is primarily to evaluate the safety and tolerability of two dose levels of an investigational drug-delivery system (LiRIS) in patients who have moderate to severe symptoms of interstitial cystitis.
- Trial name
- NCT01150565
- Testing
- LiRIS low dose and LiRIS high dose
- Where
- 3 sites in Canada
- Volunteers
- 18 people
- Sponsor
- Allergan